Physician profile
Bernard Recht
NPI 1780617100
$9,233.49
in general payments reported to CMS, 2019-2025
30 companies · $2,684 in 2025
The $2,684 reported for 2025 was more than what 82% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,140 · 2020: $616 · 2021: $748 · 2022: $1,337 · 2023: $1,390 · 2024: $1,319 · 2025: $2,684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,369 · Education: $23.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,369.01 |
| Education | $23.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,761.10 | 2019-2025 | |
| Leo Pharma INC. | $962.33 | 2019-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $934.75 | 2019-2025 | Nemluvio |
| Novartis Pharmaceuticals Corporation | $870.20 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $628.71 | 2019-2025 | Dupixent |
| Janssen Biotech, INC. | $537.17 | 2020-2025 | Tremfya, Stelara, Remicade |
| Genzyme Corporation | $524.71 | 2019-2025 | |
| Pfizer INC. | $341.26 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $339.57 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Lilly USA, LLC | $314.97 | 2019-2023 | Taltz |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $283.76 | 2019-2025 | Jublia, Arazlo, Targretin |
| Incyte Corporation | $283.05 | 2022-2025 | Opzelura |
| Amgen INC. | $278.52 | 2019-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $241.44 | 2022-2024 | Sotyktu |
| Organon LLC | $206.57 | 2025 | Vtama |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $86.05 | 2019 | |
| Arcutis Biotherapeutics, INC. | $76.25 | 2023-2024 | Zoryve |
| Dermira, INC. | $72.41 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $71.58 | 2019 | |
| Dermavant Sciences, INC. | $70.79 | 2022-2024 | Vtama |
| Ucb, INC. | $64.46 | 2019-2023 | Cimzia |
| Strata Skin Sciences, INC. | $47.04 | 2022 | |
| Almirall LLC | $41.66 | 2019-2024 | Klisyri |
| Merz North America, INC. | $40.68 | 2019 | |
| Biotissue Holdings INC. | $32.48 | 2022-2024 | |
| Journey Medical Corporation | $29.02 | 2025 | |
| Genentech USA, INC. | $25.65 | 2022 | |
| Organogenesis INC. | $24.95 | 2021 | |
| Verrica Pharmaceuticals INC. | $24.15 | 2025 | Ycanth |
| Sandoz INC. | $18.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernard Recht listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.